Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001567619-19-019921
Filing Date
2019-10-23
Accepted
2019-10-23 16:08:50
Documents
2
Period of Report
2019-10-21

Document Format Files

Seq Description Document Type Size
1 FORM 3 doc1.html 3  
1 FORM 3 doc1.xml 3 1698
2 POWER OF ATTORNEY poa_hanley.htm EX-24.1 5399
  Complete submission text file 0001567619-19-019921.txt   8549
Mailing Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746
Business Address 901 S. MOPAC EXPRESSWAY, STE. 250 BARTON OAKS PLAZA ONE AUSTIN TX 78746 (512) 942-2935
Aeglea BioTherapeutics, Inc. (Issuer) CIK: 0001636282 (see all company filings)

EIN.: 464312787 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O AEGLEA THERAPEUTICS, INC. 901 S. MOPAC EXPRESSWAY, #250 AUSTIN TX 78746
Business Address
Hanley Jr. Michael Conick (Reporting) CIK: 0001791413 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-37722 | Film No.: 191163869